{
    "clinical_study": {
        "@rank": "139804", 
        "brief_summary": {
            "textblock": "RATIONALE: An immunotoxin can locate cancer cells and kill them without harming normal\n      cells. This may be an effective treatment for hairy cell leukemia.\n\n      PURPOSE: Phase I trial to study the effectiveness of BL22 immunotoxin in treating patients\n      who have refractory or recurrent hairy cell leukemia."
        }, 
        "brief_title": "Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia", 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Hairy Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Assess the toxicity and therapeutic efficacy of recombinant BL22 immunotoxin in\n           patients with refractory or recurrent CD22+ hairy cell leukemia.\n\n        -  Define the pharmacokinetics of this drug, including the terminal elimination serum\n           half-life area under the curve and volume of distribution, in these patients.\n\n        -  Evaluate the immunogenicity of this drug in these patients.\n\n        -  Determine the effect of this drug on various components of the circulating cellular\n           immune system in these patients.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive recombinant BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5.\n      Treatment repeats at least every 42 days for up to 4 courses in the absence of disease\n      progression and sufficient neutralizing antibodies.\n\n      Cohorts of 3-6 patients receive escalating doses of recombinant BL22 immunotoxin until the\n      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more\n      than 1 of 6 patients experiences dose-limiting toxicity.\n\n      PROJECTED ACCRUAL: A maximum of 46 patients will be accrued for this study within 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed refractory or recurrent hairy cell leukemia\n\n               -  Relapsed after less than 2 years of complete remission after purine analog\n                  therapy\n\n               -  Must have at least one of the following indications for therapy:\n\n                    -  Progressive or massive splenomegaly\n\n                    -  Cytopenia defined by the following:\n\n                         -  Absolute neutrophil count less than 1,000/mm^3 OR\n\n                         -  Platelet count less than 100,000/mm^3 OR\n\n                         -  Hemoglobin less than 12 g/dL\n\n                    -  More than 20,000 hairy cells/mm^3\n\n                    -  Symptomatic adenopathy\n\n                    -  Constitutional symptoms including tumor-related fever or bone pain\n\n          -  Evidence of CD22 positivity by 1 of the following:\n\n               -  More than 15% of malignant cells from a site must react with anti-CD22 by\n                  immunohistochemistry\n\n               -  More than 30% of malignant cells from a site CD22+ by fluorescent-activated cell\n                  sorter\n\n               -  More than 400 CD22 sites/cell (average) on malignant cells as assessed by\n                  radiolabeled anti-CD22 binding\n\n          -  No CNS disease requiring treatment\n\n          -  No patients whose serum neutralizes BL22 immunotoxin in tissue culture, due to either\n             antitoxin or antimouse-IgG antibodies\n\n               -  No patients whose serum neutralizes more than 75% of the activity of 1\n                  microgram/mL of BL22 immunotoxin\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 6 months\n\n        Hematopoietic:\n\n          -  See Disease Characteristics\n\n          -  Pancytopenia due to disease allowed\n\n        Hepatic:\n\n          -  ALT and AST less than 2.5 times upper limit of normal (ULN)\n\n          -  Bilirubin less than 1.5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Pulmonary:\n\n          -  FEV1 at least 60% of predicted\n\n          -  DLCO at least 55% of predicted\n\n        Other:\n\n          -  HIV negative\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Prior bone marrow transplantation allowed\n\n          -  At least 3 weeks since prior interferon for the malignancy\n\n          -  More than 3 months since prior monoclonal antibody therapy (e.g., rituximab)\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior cytotoxic chemotherapy for the malignancy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 3 weeks since prior whole body electron beam radiotherapy for the malignancy\n\n          -  Radiotherapy within the past 3 weeks allowed provided less than 10% of total bone\n             marrow was treated and patient has measurable disease outside the radiation port\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  At least 3 weeks since prior retinoids for the malignancy\n\n          -  At least 3 weeks since any other prior systemic therapy for the malignancy\n\n          -  No concurrent therapeutic warfarin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "August 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00001792", 
            "nct_id": "NCT00021983", 
            "org_study_id": "CDR0000066835", 
            "secondary_id": [
                "NCI-99-C-0014", 
                "NCI-T98-0063"
            ]
        }, 
        "intervention": {
            "intervention_name": "BL22 immunotoxin", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Immunotoxins"
        }, 
        "keyword": "refractory hairy cell leukemia", 
        "lastchanged_date": "February 7, 2009", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NCI-99-C-0014"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892-1182"
                }, 
                "name": "Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Study of BL22, a Recombinant Immunotoxin for Treatment of CD22+ Leukemias and Lymphomas", 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "Robert Kreitman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "18596230", 
                "citation": "Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as a tumor marker for hairy cell leukemia. Blood. 2008 Sep 15;112(6):2272-7. Epub 2008 Jul 2."
            }, 
            {
                "PMID": "16061911", 
                "citation": "Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005 Sep 20;23(27):6719-29. Epub 2005 Aug 1."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00021983"
        }, 
        "results_reference": {
            "PMID": "11474661", 
            "citation": "Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2006"
    }, 
    "geocoordinates": {
        "Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support": "38.985 -77.095"
    }
}